Biological Process
| actin filament organization | | IMP | | 2290271 | PMID:15668240 | UniProtKB | PMID:15668240 |
| brain development | | IEA | Ensembl:ENSRNOP00000061371 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| cell adhesion | | TAS | | 2290271 | PMID:15668240 | UniProtKB | PMID:15668240 |
| endocytosis | | IMP | | 2290271 | PMID:15668240 | UniProtKB | PMID:15668240 |
| glucose metabolic process | | IEA | Ensembl:ENSMUSP00000048057 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| inositol phosphate metabolic process | | TAS | | 2290271 | Reactome:REACT_150154 | Reactome | Reactome:REACT_150154 |
| inositol phosphate metabolic process | | TAS | | 2290271 | Reactome:REACT_150312 | Reactome | Reactome:REACT_150312 |
| inositol trisphosphate metabolic process | | IEA | Ensembl:ENSRNOP00000061371 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| negative regulation of cell proliferation | | IEA | Ensembl:ENSMUSP00000048057 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| negative regulation of DNA replication | | IEA | Ensembl:ENSRNOP00000061371 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| negative regulation of gene expression | | IEA | Ensembl:ENSMUSP00000048057 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| negative regulation of insulin receptor signaling pathway | | IEA | Ensembl:ENSRNOP00000061371 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| negative regulation of insulin-like growth factor receptor signaling pathway | | IEA | Ensembl:ENSRNOP00000061371 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| negative regulation of MAP kinase activity | | IEA | Ensembl:ENSRNOP00000061371 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| negative regulation of neuron projection development | | IEA | Ensembl:ENSRNOP00000061371 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| negative regulation of platelet-derived growth factor receptor signaling pathway | | IEA | Ensembl:ENSRNOP00000061371 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| phosphatidylinositol biosynthetic process | | TAS | | 2290271 | Reactome:REACT_121025 | Reactome | Reactome:REACT_121025 |
| phosphatidylinositol biosynthetic process | | IEA | Ensembl:ENSMUSP00000048057 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| phosphatidylinositol dephosphorylation | | IEA | InterPro:IPR000300 | 2290271 | GO_REF:0000002 | InterPro | GO_REF:0000002 |
| phospholipid metabolic process | | TAS | | 2290271 | Reactome:REACT_120870 | Reactome | Reactome:REACT_120870 |
| phospholipid metabolic process | | TAS | | 2290271 | Reactome:REACT_121175 | Reactome | Reactome:REACT_121175 |
| post-embryonic development | | IEA | Ensembl:ENSMUSP00000048057 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| response to drug | | IEA | Ensembl:ENSRNOP00000061371 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| response to insulin stimulus | | IEA | Ensembl:ENSMUSP00000048057 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| ruffle assembly | | IEA | Ensembl:ENSMUSP00000048057 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| small molecule metabolic process | | TAS | | 2290271 | Reactome:REACT_111217 | Reactome | Reactome:REACT_111217 |
Cellular Component
| cytoplasm | | IDA | | 2290271 | GO_REF:0000052 | HPA | GO_REF:0000052 |
| cytoplasm | | IEA | Ensembl:ENSMUSP00000048057 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| cytoskeleton | | IEA | UniProtKB-SubCell:SL-0090 | 2290271 | GO_REF:0000039 | UniProtKB | GO_REF:0000039 |
| cytosol | | TAS | | 2290271 | Reactome:REACT_23874 | Reactome | Reactome:REACT_23874 |
| cytosol | | TAS | | 2290271 | Reactome:REACT_150220 | Reactome | Reactome:REACT_150220 |
| cytosol | | TAS | | 2290271 | Reactome:REACT_120976 | Reactome | Reactome:REACT_120976 |
| filopodium | | IEA | UniProtKB-SubCell:SL-0286 | 2290271 | GO_REF:0000039 | UniProtKB | GO_REF:0000039 |
| Golgi apparatus | | IDA | | 2290271 | GO_REF:0000052 | HPA | GO_REF:0000052 |
| lamellipodium | | IEA | UniProtKB-SubCell:SL-0291 | 2290271 | GO_REF:0000039 | UniProtKB | GO_REF:0000039 |
| lamellipodium | | IEA | Ensembl:ENSRNOP00000061371 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| plasma membrane | | IEA | Ensembl:ENSMUSP00000048057 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
Molecular Function
| actin binding | | IEA | UniProtKB-KW:KW-0009 | 2290271 | GO_REF:0000037 | UniProtKB | GO_REF:0000037 |
| inositol-polyphosphate 5-phosphatase activity | | IEA | Ensembl:ENSRNOP00000061371 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| phosphatidylinositol-3,4,5-trisphosphate binding | | IEA | Ensembl:ENSRNOP00000061371 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| protein binding | | IPI | UniProtKB:P56945 | 2290271 | PMID:11158326 | IntAct | PMID:11158326 |
| protein binding | | IPI | UniProtKB:Q8IV36 | 2290271 | PMID:20368287 | IntAct | PMID:20368287 |
| protein binding | | IPI | UniProtKB:Q9BX66 | 2290271 | PMID:12504111 | IntAct | PMID:12504111 |
| protein binding | | IPI | UniProtKB:Q8CI61 | 2290271 | PMID:21712384 | UniProtKB | PMID:21712384 |
| SH2 domain binding | | IPI | UniProtKB:P22681 | 2290271 | PMID:5668240 | UniProtKB | PMID:5668240 |
| SH3 domain binding | | IEA | UniProtKB-KW:KW-0729 | 2290271 | GO_REF:0000037 | UniProtKB | GO_REF:0000037 |
| 1559104 | SCL15_H | Serum cholesterol level QTL 15 (human) | 2.6 | .06 | Lipid level | hyperlipidemia susceptibility | 11 | 17086204 | 79965640 | Human |
| 1298492 | BP31_H | Blood pressure QTL 31 (human) | 2.07 | | Blood pressure | systolic | 11 | 34640077 | 123626865 | Human |
| 1357289 | AASTH31_H | Allergic/atopic asthma related QTL 31 (human) | 2 | | Reversible airflow obstruction | | 11 | 40974301 | 81574509 | Human |
| 2293009 | PRSTS194_H | Prostate tumor susceptibility QTL 194 (human) | 1.57 | | Prostate tumor susceptibility | | 11 | 54893394 | 80893394 | Human |
| 2292918 | PRSTS142_H | Prostate tumor susceptibility QTL 142 (human) | 6.12 | .000015 | Prostate tumor susceptibility | | 11 | 54893394 | 80893394 | Human |
| 2292942 | PRSTS195_H | Prostate tumor susceptibility QTL 195 (human) | 1.28 | | Prostate tumor susceptibility | | 11 | 54893394 | 80893394 | Human |
| 2316064 | GLUCO210_H | Glucose level QTL 210 (human) | | .027 | Glucose level | | 11 | 54893394 | 80893394 | Human |
| 2289174 | SADIPOQ7_H | Serum adiponectin level QTL 7 (human) | 4.2 | | Hormone level | adiponectin level | 11 | 58496495 | 120828264 | Human |
| 2289505 | BW447_H | Body weight QTL 447 (human) | 2.94 | | Body morphometry | waist to hip ratio | 11 | 59721888 | 73505325 | Human |
| 2289508 | BW452_H | Body weight QTL 452 (human) | 2.36 | | Body fat amount | abdominal | 11 | 59721888 | 73505325 | Human |
| 1643360 | BW339_H | Body weight QTL 339 (human) | 2 | | Body fat amount | percent body fat | 11 | 60505228 | 86505228 | Human |
| 1643371 | BW329_H | Body weight QTL 329 (human) | 2.64 | .0002 | Body fat amount | | 11 | 60505228 | 86505228 | Human |
| 1643405 | BMD9_H | Bone mineral density QTL 9 (human) | 2.64 | .0002 | Bone mineral density | | 11 | 60505228 | 86505228 | Human |
| 2289200 | BW356_H | Body weight QTL 356 (human) | | .0163 | Body fat amount | percent fat | 11 | 60505228 | 86505228 | Human |
| 2292771 | PRSTS33_H | Prostate tumor susceptibility QTL 33 (human) | | | Prostate tumor susceptibility | early onset | 11 | 60505228 | 86505228 | Human |
| 2300235 | PRSTS358_H | Prostate tumor susceptibility QTL 358 (human) | | .018 | Prostate tumor susceptibility | | 11 | 60505228 | 86505228 | Human |
| 2316704 | GLUCO256_H | Glucose level QTL 256 (human) | 2.98 | .00011 | Glucose level | | 11 | 65876035 | 91876035 | Human |
| 1643317 | BW233_H | Body weight QTL 233 (human) | .86 | | Body weight | body mass index | 11 | 66965521 | 92965521 | Human |
| 1643419 | BW274_H | Body Weight QTL 274 (human) | 2.19 | .0008 | Body weight | | 11 | 66965521 | 92965521 | Human |
| 1643420 | BW275_H | Body Weight QTL 275 (human) | 2.13 | .0009 | Body weight | | 21 | 66965521 | 92965521 | Human |
| 2292849 | MYI31_H | Myocardial infarction susceptibility QTL 31 (human) | | | Myocardial infarction susceptibility | early-onset | 11 | 66965521 | 92965521 | Human |
| 2292855 | MYI30_H | Myocardial infarction susceptibility QTL 30 (human) | | | Myocardial infarction susceptibility | early-onset | 11 | 66965521 | 92965521 | Human |
| 2292961 | PRSTS192_H | Prostate tumor susceptibility QTL 192 (human) | 4.51 | .0045 | Prostate tumor susceptibility | | 11 | 68844838 | 94844838 | Human |
| 2292973 | PRSTS189_H | Prostate tumor susceptibility QTL 189 (human) | 6.06 | .0029 | Prostate tumor susceptibility | | 11 | 68844838 | 94844838 | Human |
| 2301147 | PRSTS369_H | Prostate tumor susceptibility QTL 369 (human) | | | Prostate tumor susceptibility | | 11 | 68844838 | 94844838 | Human |
| 2301154 | PRSTS364_H | Prostate tumor susceptibility QTL 364 (human) | | | Prostate tumor susceptibility | | 11 | 68844838 | 94844838 | Human |